<DistDoc action="rep" dist="dist_id" distdocver="05.1" an="WSJO000020180327ee3r00105" doctype="article"><SelectData><FolderName id="302210898" rl="100">FNA US/Europe Economics</FolderName><FolderName id="302210958" rl="100">WSJ</FolderName></SelectData><ReplyItem lang="en"><BaseLang value="en" fid="la"/><IPDocId fid="id">2B4BA1B986D3E0CC56807569229D3923 SB11603097433702364731104584126742229578558</IPDocId><AccessionNo value="WSJO000020180327ee3r00105" fid="an"/><Num value="926" fid="wc"/><Date value="20180327" fid="pd"/><Time value="123000" fid="et"/><SrcCode value="wsjo" fid="sc"/><SrcName fid="sn">The Wall Street Journal Online</SrcName><TruncRules><XS value="28"/><S value="53"/><M value="80"/><L value="137"/></TruncRules><Title fid="hl"><SectionName fid="se">Business</SectionName><ColumnName fid="clm"></ColumnName><Headline fid="hd"><Para lang="en">GSK Buys Novartis's Stake in Health-Care Unit for $13 Billion; Deal is the first significant strategic move for both companies' new chief executives</Para></Headline></Title><Snippet><Para>GlaxoSmithKline PLC agreed to pay Novartis AG $13 billion for its 36.5% stake in their consumer health-care joint venture, moving to consolidate the unit just three years after the two companies joined forces.</Para></Snippet><Byline fid="by">By Nathan Allen and Noemie Bisserbe </Byline><Credit fid="cr"></Credit><Copyright fid="cy">Copyright 2018 Dow Jones &amp; Company, Inc. All Rights Reserved. </Copyright><CodeSets><CSet fid="co"><Code value="glxo"/><Code value="sndoz"/></CSet><CSet fid="in"><Code value="i257"/><Code value="i951"/></CSet><CSet fid="re"><Code value="eurz"/><Code value="uk"/><Code value="eecz"/><Code value="weurz"/></CSet><CSet fid="ns"><Code value="c184"/><Code value="c181"/><Code value="c41"/><Code value="c411"/><Code value="cactio"/><Code value="ccat"/><Code value="cslmc"/><Code value="ghea"/><Code value="c18"/><Code value="gcat"/><Code value="ncat"/><Code value="nfact"/><Code value="nfcpex"/><Code value="nfcpin"/></CSet></CodeSets></ReplyItem><MetadataPT><DocData><DocType value="article" fid="fmt"/><IPDocId fid="id">2B4BA1B986D3E0CC56807569229D3923 SB11603097433702364731104584126742229578558</IPDocId><AccessionNo value="WSJO000020180327ee3r00105" fid="an"/><Num value="926" fid="wc"/><Num value="4456" fid="cc"/><Date value="20180327" fid="pd"/><Date value="20180327" fid="upd"/><Date value="20180328" fid="md"/><Time value="123000" fid="et"/><Time value="060055" fid="upt"/><Time value="063323" fid="mt"/><BaseLang value="en" fid="la"/><Editor value="" fid="rve"/><RevisionNo value="15" fid="rvn"/></DocData><PubData><Restrictor fid="rst"><Code value="FSPNORMAWS0300"/><Code value="WSJO"/><Code value="fspFileId277761374"/><Code value="FUT"/><Code value="CLNTALL"/><Code value="CTGSMFS"/><Code value="CTGWSJ"/><Code value="DEEPWSJP"/><Code value="EN"/><Code value="IBNK"/><Code value="IFINAL"/><Code value="IINV"/><Code value="NAMZ"/><Code value="SFWSJ"/><Code value="TBAC"/><Code value="TBED"/><Code value="TBIZ"/><Code value="TBRK"/><Code value="TDJP"/><Code value="TDJWMNP"/><Code value="TFCDLIC"/><Code value="TFIN"/><Code value="TIAS"/><Code value="TIBMNB"/><Code value="TIMG"/><Code value="TINT"/><Code value="TIOP"/><Code value="TMNB"/><Code value="TMNBUS"/><Code value="TNPS"/><Code value="TNWP"/><Code value="TNWPN"/><Code value="TOPUSA"/><Code value="TSCH"/><Code value="TTRD"/><Code value="TTRK"/><Code value="TUSN"/><Code value="TWMSA"/><Code value="TYAS"/><Code value="TYLA"/><Code value="USA"/><Code value="fspWebpage"/><Code value="MPCV1M9M1B1"/><Code value="MPCEnvPROD"/><Code value="MPCDocHash76EBF5F0A098CBC8"/><Code value="FSPTHINGFINDER"/><Code value="FSPRBC"/><Code value="FSPRBCCO"/><Code value="FSPRBCCOM"/><Code value="FSP2YESCO"/><Code value="FSP2YESCOCOM"/><Code value="FSP2YESCOOC"/><Code value="FSP2YESCOCOMOC"/><Code value="FSPRBCIN"/><Code value="FSP2YESIN"/><Code value="FSPCATEGORIZER"/><Code value="FSPCATNS"/><Code value="FSPRBCNS"/><Code value="FSP2YESNS"/><Code value="FSPRBCRE"/><Code value="FSP2YESRE"/><Code value="FSP2YESPEOC"/><Code value="FSPRBC41119"/><Code value="FSPRBC472361"/><Code value="FSPRBC611290"/><Code value="FSPRBC648059"/><Code value="FSPRBC695338"/><Code value="FSPRBC700958"/><Code value="FSPRBC716801"/><Code value="FSPRBC721131"/><Code value="FSPRBC776179"/><Code value="FSPRBC799842"/><Code value="FSPRBC802123"/><Code value="FSPRBC803818"/><Code value="FSPRBC803821"/><Code value="FSPRBC829135"/><Code value="FSPRBC830855"/><Code value="FSPRBC831127"/><Code value="FSPRBC831148"/><Code value="FSPRBC831151"/><Code value="FSPRBC833120"/><Code value="FSPRBC849276"/><Code value="FSPRBC849536"/><Code value="FSPRBC849556"/><Code value="FSPRBC849559"/><Code value="FSPRBC857619"/><Code value="FSPRBC857620"/><Code value="FSPRBC857647"/><Code value="FSPRBC857648"/><Code value="FSPRBC860206"/><Code value="FSPRBC860230"/><Code value="FSPRBC860329"/><Code value="FSPRBC860348"/><Code value="FSPRBC860376"/><Code value="FSPRBC860440"/><Code value="FSPRBC861918"/><Code value="MPCCL"/><Code value="MPCJP"/><Code value="MPCKW"/><Code value="MPCKP"/><Code value="MPCESRE"/><Code value="MPCESIN"/><Code value="MPCESNS"/><Code value="FSP2AC"/></Restrictor><IPId value="DJENT" fid="ip"/><PublisherN fid="pub">Dow Jones &amp; Company, Inc.</PublisherN><AttribCode value="WSJO2" fid="atr"/><SrcCode value="WSJO" fid="sc"/><SrcName fid="sn">The Wall Street Journal Online</SrcName><Logo img="wsjoLogo.gif" link="" src="http://logos.factiva.com"/></PubData><CodeSets><CSet fid="co"><Code value="glxo"><CodeD index="no" lang="en">GlaxoSmithKline PLC</CodeD><CodeI org="thingfinder" action="add"><CodeA name="db" value="ptf--aboutCo-00004107-20180322-231424.dictionary"/></CodeI><CodeI org="rbc" action="add"><CodeA name="rule" value="41119"/><CodeA name="db" value="prbc---00018593-20180327-195122"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI></Code><Code value="sndoz"><CodeD index="no" lang="en">Novartis AG</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="472361"/><CodeA name="db" value="prbc---00018593-20180327-195122"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI></Code></CSet><CSet fid="in"><Code value="i257"><CodeD index="no" lang="en">Pharmaceuticals</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="802123"/><CodeA name="db" value="prbc---00018593-20180327-195122"/><CodeA name="rule" value="831127"/><CodeA name="rule" value="849536"/></CodeI><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="root" value="co:glxo"/><CodeA name="root" value="co:sndoz"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="1"/></CodeI></Code><Code value="i951"><CodeD index="no" lang="en">Health Care/Life Sciences</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="861918"/><CodeA name="db" value="prbc---00018593-20180327-195122"/><CodeA name="rule" value="721131"/></CodeI><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="root" value="in:i257"/><CodeA name="root" value="in:i257"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="0"/></CodeI></Code></CSet><CSet fid="re"><Code value="eurz"><CodeD index="no" lang="en">Europe</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="857648"/><CodeA name="db" value="prbc---00018593-20180327-195122"/></CodeI><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="root" value="re:uk"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="0"/></CodeI></Code><Code value="uk"><CodeD index="no" lang="en">United Kingdom</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="857620"/><CodeA name="db" value="prbc---00018593-20180327-195122"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="2"/></CodeI></Code><Code value="eecz"><CodeD index="no" lang="en">European Union Countries</CodeD><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="root" value="re:uk"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="1"/></CodeI></Code><Code value="weurz"><CodeD index="no" lang="en">Western Europe</CodeD><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="root" value="re:uk"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="1"/></CodeI></Code></CSet><CSet fid="ns"><Code value="c184"><CodeD index="no" lang="en">Joint Ventures/Consortia</CodeD><CodeI org="categoriser" action="add"><CodeA name="db" value="es-EnglishNS_en_20180322142639"/><CodeA name="es_score" value="200"/></CodeI><CodeI org="rbc" action="add"><CodeA name="rule" value="860329"/><CodeA name="db" value="prbc---00018593-20180327-195122"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="2"/><CodeA name="nodelevel" value="3"/></CodeI></Code><Code value="c181"><CodeD index="no" lang="en">Acquisitions/Mergers/Shareholdings</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="829135"/><CodeA name="db" value="prbc---00018593-20180327-195122"/><CodeA name="rule" value="860440"/><CodeA name="rule" value="695338"/><CodeA name="rule" value="700958"/><CodeA name="rule" value="611290"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="2"/><CodeA name="nodelevel" value="3"/></CodeI></Code><Code value="c41"><CodeD index="no" lang="en">Management</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="860348"/><CodeA name="db" value="prbc---00018593-20180327-195122"/><CodeA name="rule" value="648059"/></CodeI><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="root" value="ns:c411"/><CodeA name="root" value="ns:cslmc"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="1"/></CodeI></Code><Code value="c411"><CodeD index="no" lang="en">Management Moves</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="860376"/><CodeA name="db" value="prbc---00018593-20180327-195122"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="2"/></CodeI></Code><Code value="cactio"><CodeD index="no" lang="en">Corporate Actions</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="860206"/><CodeA name="db" value="prbc---00018593-20180327-195122"/></CodeI><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="root" value="ns:c184"/><CodeA name="root" value="ns:c181"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="1"/></CodeI></Code><Code value="ccat"><CodeD index="no" lang="en">Corporate/Industrial News</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="831148"/><CodeA name="db" value="prbc---00018593-20180327-195122"/><CodeA name="rule" value="857619"/><CodeA name="rule" value="857647"/><CodeA name="rule" value="803818"/><CodeA name="rule" value="849556"/></CodeI><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="root" value="ns:c184"/><CodeA name="root" value="ns:c181"/><CodeA name="root" value="ns:c41"/><CodeA name="root" value="ns:c411"/><CodeA name="root" value="ns:cactio"/><CodeA name="root" value="ns:cslmc"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="0"/></CodeI></Code><Code value="cslmc"><CodeD index="no" lang="en">Senior Level Management</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="860230"/><CodeA name="db" value="prbc---00018593-20180327-195122"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="2"/></CodeI></Code><Code value="ghea"><CodeD index="no" lang="en">Health</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="799842"/><CodeA name="db" value="prbc---00018593-20180327-195122"/><CodeA name="rule" value="849276"/><CodeA name="rule" value="803821"/><CodeA name="rule" value="830855"/><CodeA name="rule" value="831151"/><CodeA name="rule" value="849559"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="1"/></CodeI></Code><Code value="c18"><CodeD index="no" lang="en">Ownership Changes</CodeD><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="root" value="ns:c184"/><CodeA name="root" value="ns:c181"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="1"/><CodeA name="nodelevel" value="2"/></CodeI></Code><Code value="gcat"><CodeD index="no" lang="en">Political/General News</CodeD><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="root" value="ns:ghea"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="nodelevel" value="0"/></CodeI></Code><Code value="ncat"><CodeD index="no" lang="en">Content Types</CodeD><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="root" value="ns:c184"/><CodeA name="root" value="ns:c181"/><CodeA name="root" value="ns:c41"/><CodeA name="root" value="ns:c411"/><CodeA name="root" value="ns:cslmc"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI></Code><Code value="nfact"><CodeD index="no" lang="en">Factiva Filters</CodeD><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="root" value="ns:c184"/><CodeA name="root" value="ns:c181"/><CodeA name="root" value="ns:c41"/><CodeA name="root" value="ns:c411"/><CodeA name="root" value="ns:cslmc"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI></Code><Code value="nfcpex"><CodeD index="no" lang="en">C&amp;E Executive News Filter</CodeD><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="root" value="ns:c411"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI></Code><Code value="nfcpin"><CodeD index="no" lang="en">C&amp;E Industry News Filter</CodeD><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="root" value="ns:c184"/><CodeA name="root" value="ns:c181"/><CodeA name="root" value="ns:c41"/><CodeA name="root" value="ns:c411"/><CodeA name="root" value="ns:cslmc"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00001004-20180327-161428"/><CodeA name="status" value="active"/></CodeI></Code></CSet></CodeSets><DescTPC fid="de"><DescField fid="ipc">GSK GSK.LN M/HCR N/CAC N/COF N/DVT N/JVN N/MNT N/PER N/TNM NOVN.EB NVS PFE </DescField><DescField fid="ipd">WSJ WSJ.com WSJ.com Site Search WSJAsia WSJEurope WSJ Japanese Online WSJ-PRO-WSJ.com WSJSunday DRUG GLAXOSMITHKLINE GSK HEALTH CARE JOINT VENTURE NOVARTIS SB116030974337023647311045841267422295785588 Narasimhan, Vasant Walmsley, Emma SYND CODES_REVIEWED European Business News </DescField><DescField fid="ipcns">OBUK OEUR </DescField><DescField fid="ipcconame">GlaxoSmithKline Novartis </DescField><DescField fid="ipccodj">GSK.LN NOVN.EB PFE </DescField></DescTPC></MetadataPT><ArchiveDoc xml:space="preserve"><Article markup="pp0" lang="en" index="field"><HandL fid="hlp"><Title fid="hl"><SectionName fid="se" index="field">Business</SectionName><ColumnName fid="clm" index="field"></ColumnName><Headline fid="hd"><Para lang="en">GSK Buys Novartis's Stake in Health-Care Unit for $13 Billion; Deal is the first significant strategic move for both companies' new chief executives</Para></Headline></Title><LeadPara fid="lp"><Para>GlaxoSmithKline PLC agreed to pay Novartis AG $13 billion for its 36.5% stake in their consumer health-care joint venture, moving to consolidate the unit just three years after the two companies joined forces.</Para><Para>The deal is the first significant strategic move for both companies' young and newly installed chief executives, as they reposition their respective firms amid a series of other reviews and deal making across the industry.</Para></LeadPara></HandL><TailParas fid="td"><Para>GSK Chief Executive Emma Walmsley, 48 years old, has moved to shake up the company's drug-research efforts, <ELink type="webpage" ref="https://www.wsj.com/articles/glaxo-ceo-dispenses-bitter-pill-to-fix-r-d-1521979200">reshuffling or letting go hundreds of executives and scientists</ELink> since taking over about a year ago. That is part of a broader industrywide effort at several big pharmaceutical firms—including Novartis—to refocus attention and resources on the high-risk, but high-reward business of discovering and bringing to market new drugs.</Para><Para>Amid that push, both have also been considering how to prune, or bolster, their businesses at the deal table. GSK was among several companies kicking the tires at Pfizer Inc.'s large consumer-health business, but last week said it wouldn't bid. Novartis, meanwhile, is considering a <ELink type="webpage" ref="https://www.wsj.com/articles/novartis-announces-share-buyback-as-dollar-hits-earnings-1485325279">sale or spin off its Alcon eye business</ELink>, while also weighing options for its U.S. generics business.</Para><Para>Novartis Chief Executive Vasant Narasimhan, 41, on the job just since February, has similarly said his main aim is to <ELink type="webpage" ref="https://www.wsj.com/articles/novartis-ceo-steers-drug-maker-back-to-r-d-1518962400">reinvigorate the company's drug-discovery pipeline</ELink>. As part of a <ELink type="webpage" ref="https://www.wsj.com/articles/novartis-overhauls-product-portfolio-in-transactions-valued-at-more-than-25-billion-1398144997">deal announced in 2014 and completed the next year </ELink>that created the joint venture, Novartis starting this month was entitled to require GSK to buy the rest of its stake.</Para><Para>"While our consumer health-care joint venture with GSK is progressing well, the time is right for Novartis to divest a noncore asset at an attractive price," Dr. Narasimhan said in a statement. The proceeds of the deal will be used to fund shareholder returns and pursue bolt-on acquisitions, he said.</Para><Para>Ms. Walmsley characterized the deal as a way of anchoring her own efforts at refocusing the company on research and development. The slower-growing, but often steadier, sales from consumer-health products, like toothpaste and over-the-counter cough and flu medicine, can serve as a crutch for the often more volatile business of creating and marketing new drugs.</Para><Para>"Our number one priority is the strengthening of our pharma business and at the heart of that is R&amp;D and its pipeline," said Ms. Walmsley in a conference call with reporters. This deal "brings more certainty" and "allows us the flexibility to invest in R&amp;D as appropriate," she said.</Para><Para>Investors in both companies endorsed the deal. Shares in GSK were up 6.4% in afternoon trading in London, while Novartis rose 2.2% in Zurich.</Para><Para>Ms. Walmsley ran GSK's consumer-health business for more than five years <ELink type="webpage" ref="https://www.wsj.com/articles/glaxos-new-ceo-is-a-steady-hand-in-pharmaceuticals-rolling-seas-1490952607">before taking over as CEO in April 2017</ELink>. Her predecessor, Andrew Witty, agreed with Novartis to combine their consumer-health businesses, creating a giant that brought some of the world's best-known brands under one roof—including Excedrin pain medicine, antismoking aides like NiQuitin and Theraflu cold medicine.</Para><Para>That was just one part of a bigger series of transactions between the two. The deals beefed up GSK's consumer health and vaccines footprint. Novartis, meanwhile, bought GSK's cancer drugs business.</Para><Para>Under the terms of the transaction, the joint venture's four Novartis-appointed directors will step down, Novartis said.</Para><Para>Following completion, GSK said it expects the deal to boost earnings in 2018 and strengthen cash flow, while the business should post operating margins in the mid-20% range by 2022. GSK said it would also begin a strategic review of its Horlicks brand and other consumer-nutrition products with a view to funding transactions. Most of Horlicks and other nutrition products sales are in India, said Ms. Walmsley.</Para><Para>The deal, which is expected to close in the second quarter, is subject to approval from GSK shareholders.</Para><Para>Write to Noemie Bisserbe at <ELink type="webpage" ref="mailto:noemie.bisserbe@wsj.com">noemie.bisserbe@wsj.com</ELink></Para><Para>Market Talk</Para><Para>* The sale is beneficial for both companies, says Bryan Garnier. The $13 billion price tag is at a decent premium to his valuation of $11 billion to $12 billion and will give Novartis the financial flexibility to go after more acquisitions, says the bank. The sale also reinforces the Swiss company's strategy to streamline its operations and focus more on pharmaceuticals, while GSK stands to benefit as the unit will boost earnings per share immediately, despite the high price, says the bank. (nathan.allen@dowjones.com)</Para><Para>* Glaxo's decision to take full ownership of its consumer-health joint venture should boost its earnings and allow the latter to make bolt-on acquisitions, says Jefferies. Jefferies says Novartis is likely to do deals fairly quickly to help offset any share dilution. Part of the timing of the decision may have been triggered by an imminent bolt-on deal, the brokerage says. "It also wouldn't be a surprise to see a new share buy-back program being announced at some point." Jefferies reckons the deal should generate at least 3%-4% adjusted earnings per share accretion for Glaxo in the near to mid-term. (philip.waller@wsj.com)</Para><Para>* To learn more about Market Talk and Dow Jones' real-time coverage of markets, companies and events, please visit <ELink type="webpage" ref="https://www.dowjones.com/products/newswires/">https://www.dowjones.com/products/newswires/</ELink></Para></TailParas><Byline fid="by" index="field">By Nathan Allen and Noemie Bisserbe </Byline><Credit fid="cr" index="field"></Credit><Contact fid="ct" index="field"></Contact><Notes fid="rf" index="field"></Notes><Art fid="art" index="field"></Art><Copyright fid="cy" index="field">Copyright 2018 Dow Jones &amp; Company, Inc. All Rights Reserved. </Copyright></Article></ArchiveDoc><AdocTOC adoctype="article"><Item size="0" ref="distdoc:archive/ArchiveDoc::Article" type="arttext"></Item><Item size="0" ref="distdoc:archive/InvertText" type="invtext"></Item><Item subtype="primary" size="0" ref="https://www.wsj.com/articles/gsk-to-buy-out-novartiss-stake-in-health-care-venture-for-13-billion-1522130448" type="webpage"></Item></AdocTOC></DistDoc>

